65640 Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; U.S.-Bilateral Collaborative 

Research Partnerships (CRP) on the 

Prevention of HIV/AIDS and Co-morbidities 

(R21). 

Date: December 1–2, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville, 1750 

Rockville Pike, Regency, Rockville, MD 

20852. 

Contact Person: Eugene R. Baizman, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIAID/NIH/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892, 301–402– 

1464, eb237e@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 20, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–27055 Filed 10–25–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Cellular, Tissue and Gene Therapies 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

teleconference meeting of a public 

advisory committee of the Food and 

Drug Administration (FDA). At least one 

portion of the meeting will be closed to 

the public. 

Name of Committee: Cellular, Tissue 

and Gene Therapies Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The teleconference 

meeting will be held on December 14, 

2010, from 3 p.m. to 6 p.m. EST. 

Location: National Institutes of Health 

(NIH). Bldg. 29B, Conference Room C. 

The public is welcome to attend the 

meeting at the specified location where 

a speakerphone will be provided. Public 

participation in the meeting is limited to 

the use of the speakerphone in the 

conference room. Important information 

about transportation and directions to 

the NIH campus, parking and security 

procedures is available on the Internet 

at http://www.nih.gov/about/visitor/ 

index.htm. (FDA has verified the Web 

site address, but FDA is not responsible 

for any subsequent changes to the Web 

site after this document publishes in the 

Federal Register.) Visitors must show 

two forms of identification, one of 

which must be a government-issued 

photo identification such as a Federal 

employee badge, driver’s license, 

passport, green card, etc. Detailed 

information about security procedures is 

located at http://www.nih.gov/about/ 

visitorsecurity.htm. Due to the limited 

available parking, visitors are 

encouraged to use public transportation. 

Contact Person: Gail Dapolito or 

Sheryl Clark, Center for Biologics 

Evaluation and Research (HFM–71), 

Food and Drug Administration, 1401 

Rockville Pike, Rockville MD 20852, 

301–827–0314, or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512389. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the Agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On December 14, 2010, the 

committee will meet in open session to 

hear updates of the research programs in 

the Tumor Vaccines and Biotechnology 

Branch, Office of Cellular, Tissue and 

Gene Therapies, Center for Biologics 

Evaluation and Research, FDA. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: On December 14, 2010, 

from 3 p.m. to 5 p.m. the meeting is 

open to the public. Interested persons 

may present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before December 7, 2010. 

Oral presentations from the public will 

be scheduled between approximately 4 

p.m. and 5 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before November 29, 2010. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

November 30, 2010. 

Closed Committee Deliberations: On 

December 14, 2010, from 5 p.m. to 6 

p.m., the meeting will be closed to 

permit discussion where disclosure 

would constitute a clearly unwarranted 

invasion of personal privacy (5 U.S.C. 

552b(c)(6)). The committee will discuss 

a report of intramural research programs 

and make recommendations regarding 

personnel staffing decisions. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Gail Dapolito 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices 65641 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 21, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27063 Filed 10–25–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Risk Communication Advisory 

Committee; Amendment of Notice 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

The Food and Drug Administration 

(FDA) is announcing an amendment to 

the notice of meeting of the Risk 

Communication Advisory Committee. 

This meeting was announced in the 

Federal Register of September 20, 2010 

(75 FR 57279). The amendment is being 

made to reflect a change in the Agenda 

portion of the document. There are no 

other changes. 

FOR FURTHER INFORMATION CONTACT: Lee 

L. Zwanziger, Office of Policy, Planning 

and Budget, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 32, Rm. 3278, Silver Spring, 

MD 20993, 301–796–9151, FAX: 301– 

847–8611, e-mail: RCAC@fda.hhs.gov, 

or FDA Advisory Committee 

Information Line, 1–800–741–8138 

(301–443–0572 in the Washington, DC 

area), code 8732112560. Please call the 

Information Line for up-to-date 

information on this meeting. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of September 20, 2010, 

FDA announced that a meeting of the 

Risk Communication Advisory 

Committee would be held on November 

8 and 9, 2010. On page 57280, in the 

first column, the Agenda portion of the 

document is changed to read as follows: 

Agenda: On November 8 and 9, 2010, 

the Committee will hear and discuss 

developments in FDA’s ongoing 

communications programs, such as 

FDA’s Strategic Plan for Risk 

Communication, FDA’s Transparency 

Initiative, foodborne outbreaks and 

related recall communications, and the 

challenges of effectively communicating 

with patients and caregivers about 

appropriate use of medical devices 

when a patient is prescribed a medical 

device for home use. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to the advisory committees. 

Dated: October 21, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–27060 Filed 10–25–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Tobacco Products Scientific Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Tobacco 

Products Scientific Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 18, 2010, from 1 p.m. 

until 5 p.m. 

Location: FDA White Oak Conference 

Center, 10903 New Hampshire Ave., 

Bldg. 31, rm. 1503, Silver Spring, MD 

20993–0002. Information regarding 

special accommodations due to a 

disability, visitor parking, and 

transportation may be accessed at: 

http://www.fda.gov/ 

AdvisoryCommittees/default.htm; under 

the heading ‘‘Resources for You’’ click 

on ‘‘White Oak Conference Center 

Parking and Transportation Information 

for FDA Advisory Committee Meetings.’’ 

Contact Person: Caryn Cohen, Office 

of Science, Center for Tobacco Products, 

Food and Drug Administration, 9200 

Corporate Blvd., Rockville, MD 20850, 

1–877–287–1373 (choose Option 4), 

e-mail: TPSAC@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

8732110002. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the Agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On November 18, 2010, the 

committee will (1) Receive an update on 

the Menthol Report Subcommittee and 

(2) receive and discuss presentations 

regarding the data requested by the 

committee at the March 30 and 31, 

2010, meeting of the Tobacco Products 

Scientific Advisory Committee. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before November 9, 2010. 

Oral presentations from the public will 

be scheduled between approximately 3 

p.m. and 4 p.m. on November 18, 2010. 

Those desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before 

November 1, 2010. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by November 2, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Caryn Cohen 


emcdonald on DSK2BSOYB1PROD with NOTICES